Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) Research & Development (2016 - 2024)

Rockwell Medical's Research & Development history spans 15 years, with the latest figure at $1000.0 for Q4 2024.

  • For Q4 2024, Research & Development fell 99.38% year-over-year to $1000.0; the TTM value through Sep 2025 reached $1000.0, down 99.44%, while the annual FY2024 figure was $19000.0, 98.27% down from the prior year.
  • Research & Development reached $1000.0 in Q4 2024 per RMTI's latest filing, down from $18000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.4 million in Q2 2021 to a low of $1000.0 in Q4 2024.
  • Average Research & Development over 5 years is $1.0 million, with a median of $1.1 million recorded in 2021.
  • Peak YoY movement for Research & Development: skyrocketed 266.4% in 2020, then plummeted 99.38% in 2024.
  • A 5-year view of Research & Development shows it stood at $1.9 million in 2020, then fell by 27.49% to $1.4 million in 2021, then tumbled by 90.14% to $137000.0 in 2022, then increased by 17.52% to $161000.0 in 2023, then tumbled by 99.38% to $1000.0 in 2024.
  • Per Business Quant, the three most recent readings for RMTI's Research & Development are $1000.0 (Q4 2024), $18000.0 (Q1 2024), and $161000.0 (Q4 2023).